Richard P Allen1, Christopher J Earley2, Byron C Jones3, Erica L Unger4. 1. Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address: richardjhu@mac.com. 2. Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 3. Department of Genetics, Genomics and Informatics, University of Tennessee, Memphis, TN, USA. 4. Department of Biology, Lebanon Valley College, Annville, PA, USA.
Abstract
BACKGROUND: Brain iron deficiency (BID), especially for the substantia nigra (SN), without peripheral iron deficiency (ID) has been well documented as a ubiquitous finding for restless legs syndrome (RLS) patients. This close association suggests the biology of RLS BID can produce RLS symptoms. Association, however, cannot establish such a direct relationship. Instead, the BID of RLS could be experimentally produced to determine if it then produces significant RLS-like biological or behavioral features. Forward genetics approach led to identification from the BXD strains the BXD40 females (BXD40f) as a putative animal model for the RLS BID. The BXD40f on an iron-sufficient diet have a lower iron in the VMB (containing the SN) during the active but not inactive period. This was not found for the other BXD strains evaluated. The BXD40f on an ID diet uniquely have even greater reduced VMB but not peripheral iron, matching the RLS BID pathophysiology. A prior report found that the BXD40f on an iron-sufficient diet had an RLS-like behavior of increased activity occurring only in the last part of the active period that was not present in the other strains without the low VMB iron. This increased activity matches the circadian pattern of symptoms in RLS patients with increased urge or drive to move in the last part of the day. This study asks first: if you decrease the VMB iron by an iron deficient diet do the RLS-like behaviors worsen; and second will the dopaminergic treatments effective for RLS also reduce the worsened RLSlike behaviors. METHODS: In sum, 13 BXD40f mice post weaning were randomly assigned for 100 days to either a iron-sufficient diet (n = 6) or an ID diet (N = 7). They were then evaluated for 24-h activity in their home cage using implanted G2 EMitter telemetry device. At 3 h before the end of the active period IP doses were given every other day of either: saline (vehicle only), 12.5 mg levodopa, 25 mg levodopa, 0.5 mg quinpirole, or 1 0.0 mg quinpirole. RESULTS: The ID compared to irons-sufficient diet produced earlier onset of the RLS-like behavior matching the earlier onset of symptoms with increasing severity of RLS. The dopaminergic treatments significantly reduced the RLS-like behavior. Added analyses of the RLS-like behaviors as decreased resting times showed similar results to activity increases. CONCLUSIONS: These data demonstrate both that The BXD40f provide a useful animal model of RLS and also strongly support the hypothesis that the biology of RLS BID can produce RLS symptoms.
BACKGROUND:Brain iron deficiency (BID), especially for the substantia nigra (SN), without peripheral iron deficiency (ID) has been well documented as a ubiquitous finding for restless legs syndrome (RLS) patients. This close association suggests the biology of RLSBID can produce RLS symptoms. Association, however, cannot establish such a direct relationship. Instead, the BID of RLS could be experimentally produced to determine if it then produces significant RLS-like biological or behavioral features. Forward genetics approach led to identification from the BXD strains the BXD40 females (BXD40f) as a putative animal model for the RLSBID. The BXD40f on an iron-sufficient diet have a lower iron in the VMB (containing the SN) during the active but not inactive period. This was not found for the other BXD strains evaluated. The BXD40f on an ID diet uniquely have even greater reduced VMB but not peripheral iron, matching the RLSBID pathophysiology. A prior report found that the BXD40f on an iron-sufficient diet had an RLS-like behavior of increased activity occurring only in the last part of the active period that was not present in the other strains without the low VMB iron. This increased activity matches the circadian pattern of symptoms in RLSpatients with increased urge or drive to move in the last part of the day. This study asks first: if you decrease the VMB iron by an iron deficient diet do the RLS-like behaviors worsen; and second will the dopaminergic treatments effective for RLS also reduce the worsened RLSlike behaviors. METHODS: In sum, 13 BXD40f mice post weaning were randomly assigned for 100 days to either a iron-sufficient diet (n = 6) or an ID diet (N = 7). They were then evaluated for 24-h activity in their home cage using implanted G2 EMitter telemetry device. At 3 h before the end of the active period IP doses were given every other day of either: saline (vehicle only), 12.5 mg levodopa, 25 mg levodopa, 0.5 mg quinpirole, or 1 0.0 mg quinpirole. RESULTS: The ID compared to irons-sufficient diet produced earlier onset of the RLS-like behavior matching the earlier onset of symptoms with increasing severity of RLS. The dopaminergic treatments significantly reduced the RLS-like behavior. Added analyses of the RLS-like behaviors as decreased resting times showed similar results to activity increases. CONCLUSIONS: These data demonstrate both that The BXD40f provide a useful animal model of RLS and also strongly support the hypothesis that the biology of RLSBID can produce RLS symptoms.
Authors: Lina Yin; Erica L Unger; Leslie C Jellen; Christopher J Earley; Richard P Allen; Ann Tomaszewicz; James C Fleet; Byron C Jones Journal: Am J Physiol Regul Integr Comp Physiol Date: 2012-03-28 Impact factor: 3.619
Authors: Richard P Allen; Nathan C Donelson; Byron C Jones; Yuqing Li; Mauro Manconi; David B Rye; Subhabrata Sanyal; Juliane Winkelmann Journal: Sleep Med Date: 2016-09-02 Impact factor: 3.492
Authors: Amanda M Snyder; XinSheng Wang; Stephanie M Patton; Paolo Arosio; Sonia Levi; Christopher J Earley; Richard P Allen; James R Connor Journal: J Neuropathol Exp Neurol Date: 2009-11 Impact factor: 3.685
Authors: James R Connor; Xin-Sheng Wang; Richard P Allen; John L Beard; Jason A Wiesinger; Barbara T Felt; Christopher J Earley Journal: Brain Date: 2009-05-25 Impact factor: 13.501
Authors: Hye-Jin Moon; Yongmin Chang; Yeong Seon Lee; Huijin Song; Hyuk Won Chang; Jeonghun Ku; Richard P Allen; Christopher J Earley; Yong Won Cho Journal: Med Devices (Auckl) Date: 2015-07-30
Authors: Aaro V Salminen; Stefan Clemens; Diego García-Borreguero; Imad Ghorayeb; Yuqing Li; Mauro Manconi; William Ondo; David Rye; Jerome M Siegel; Alessandro Silvani; John W Winkelman; Richard P Allen; Sergi Ferré Journal: Dis Model Mech Date: 2022-08-10 Impact factor: 5.732
Authors: Aaro V Salminen; Alessandro Silvani; Richard P Allen; Stefan Clemens; Diego Garcia-Borreguero; Imad Ghorayeb; Sergi Ferré; Yuqing Li; William Ondo; Daniel L Picchietti; David Rye; Jerome M Siegel; John W Winkelman; Mauro Manconi Journal: Mov Disord Date: 2020-12-31 Impact factor: 10.338